CombiGene AB (“CombiGene”, the “Company”) today announces that CEO Jan Nilsson will leave his position as
STOCKHOLM — January 9, 2023. CombiGene AB (“CombiGene”, the “Company”) and the Danish company Zyneyro ApS
STOCKHOLM, October 12, 2021 — CombiGene AB (‘CombiGene’ or the ‘Company’) and Spark Therapeutics, a member
The board of directors of CombiGene AB (publ) ("CombiGene”) has prepared an EU Growth Prospectus relating
The board of directors of CombiGene AB (publ) (“CombiGene”) has today, based on the authorisation from
After having carried out a successful pilot production of CG01 in July at the Spanish gene
CombiGene AB (publ) ("CombiGene" or the "Company") has today decided to carry out a directed share
CombiGene AB (publ) (”CombiGene” or the ”Company”) has today resolved to conduct a private placement of
The Board of Directors in Combigene AB (“Combigene” or the “Company”), reg. no. 556403-3818, has today,
Collaboration supports progression of Epilepsy Gene Therapy toward clinical trials CombiGene AB (publ) (“CombiGene”), a leading